Inclusion Criteria:  Histologically or cytologically confirmed, previously untreated and surgically resectable non-small cell lung cancer (stage II-IIIA, patients with squamous cell carcinoma or EGFR mutation should not be included); Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Satisfactory preoperative laboratory testing and adequate pulmonary function for surgery; Patients approve and sign the informed consent.  Exclusion Criteria:  Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoid carcinoma; Patients with active autoimmune disease or history of autoimmune disease; Patients who have a condition requiring systemic treatment with either prednisone or other immunosuppressive medications; Patients with a history of symptomatic interstitial lung disease; History of allergy to study drug components; Women must not be pregnant or breast-feeding; Men with female partners that are not willing to use contraception; Patients who have received prior chemotherapy, anti-angiogenesis therapy and immunotherapy for this malignancy or for any other past malignancy; Patients who have received prior treatment for non-small cell lung cancer; Any mental or psychological condition which would not permit the patient to complete the study or understand the patient information; Patients who have major hemoptysis within the past 4 weeks, tumor has invasion or is close to great vessels; Patients with high risk of major bleeding; Patients who have arterial thrombotic events, esophageal varices, peptic ulcers, wounds or bone fractures; Patients who have prior malignancies; HIV, HBV, HCV infection or active pulmonary tuberculosis; Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.